← Back to Search

Neuromuscular Blocker

Rocuronium IV bolus 0.1 mg/kg guided by TOF 0/4 and PTC≤ 2 for Laparoscopic Colorectal Surgery

Phase 4
Waitlist Available
Led By Philippe PR Richebé, MD PhD
Research Sponsored by Ciusss de L'Est de l'Île de Montréal
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up every 30 minutes from t0 = arrival in pacu until discharge from pacu, up to 3 hours
Awards & highlights

Study Summary

This study is evaluating whether a drug called NMB has a positive impact on pain and recovery after surgery.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~every 30 minutes from t0 = arrival in pacu until discharge from pacu, up to 3 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and every 30 minutes from t0 = arrival in pacu until discharge from pacu, up to 3 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Total intra-operative remifentanil consumption during surgery in mcg/kg/h
Secondary outcome measures
Insufflation
Amount of opioids received in 24h as Patient Controlled Analgesia in mg
Area Under the Curve (AUCs) whenever the NOL is above 25, no unit
+19 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Group "D" for Deep muscle relaxation, high doses rocuroniumExperimental Treatment1 Intervention
A bolus of 0.4 mg/kg of IV rocuronium will be given at the induction of the anesthesia. Bolus of rocuronium 0.1 mg/kg IV will be given during surgery to keep the TOF 0/4 and a PTC ≤ 2 (parameters measured every 10 minutes).
Group II: Group "M" for Moderate muscle relaxation, low doses rocuroniumActive Control1 Intervention
A bolus of 0.4 mg/kg of IV rocuronium will be given at the induction of the anesthesia. Rocuronium IV bolus guided by TOF that must remain between 1-3 / 4 during surgery.

Find a Location

Who is running the clinical trial?

Ciusss de L'Est de l'Île de MontréalLead Sponsor
70 Previous Clinical Trials
5,460 Total Patients Enrolled
Merck Canada Inc.Industry Sponsor
11 Previous Clinical Trials
1,418 Total Patients Enrolled
Philippe PR Richebé, MD PhDPrincipal InvestigatorCIUSSS Est de l'île de Montréal
5 Previous Clinical Trials
306 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Impact of Intraoperative Deep Neuromuscular Blockade on NOL-guided Opioid Requirement in LSC Colorectal Surgeries
Philippe Richebe 2019. "Impact of Intraoperative Deep Neuromuscular Blockade on NOL-guided Opioid Requirement in LSC Colorectal Surgeries". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03910998.
~17 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top